When Cold Is Hot: Immune Checkpoint Inhibition Therapy for Rhabdoid Tumors

Mark Yarmarkovich; John M Maris

doi:10.1016/j.ccell.2019.11.006

When Cold Is Hot: Immune Checkpoint Inhibition Therapy for Rhabdoid Tumors

Cancer Cell. 2019 Dec 9;36(6):575-576. doi: 10.1016/j.ccell.2019.11.006.

Authors

Mark Yarmarkovich¹, John M Maris²

Affiliations

¹ Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
² Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA, USA; Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA; Abramson Family Cancer Research Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. Electronic address: maris@email.chop.edu.

PMID: 31951557
DOI: 10.1016/j.ccell.2019.11.006

Abstract

Carcinogen-induced cancers typically have high mutation burdens and an inflamed microenvironment and thus are poised to respond to immune checkpoint inhibitors (ICIs). However, cancers with loss-of-function mutations in the SWI/SNF complex have few additional mutations yet also have an inflamed immunophenotype and should respond to ICI therapy.

Publication types

Review

MeSH terms

Chromatin Assembly and Disassembly / immunology*
DNA Helicases / genetics
Humans
Immunotherapy* / methods
Mutation / genetics
Nuclear Proteins / genetics
Nuclear Proteins / immunology*
Rhabdoid Tumor / drug therapy*
Rhabdoid Tumor / genetics
Transcription Factors / genetics

Substances

Nuclear Proteins
Transcription Factors
DNA Helicases